Eikon Therapeutics Q1 2026 net loss $83M, cash $596M; three oncology programs advance

Eikon Therapeutics, Inc.

2026-Q1 EPS reported -$2.46

Net loss $83M (Q1 2026) vs $74.5M (Q1 2025); R&D expenses $70M (+24%) incl. $5M milestone to Impact Therapeutics.
Cash, equivalents and marketable securities $596M at March 31, 2026; expected to fund operations into H2 2027.
EIK1001: Phase 2 NSCLC trial fully enrolled; updated data at ASCO; Phase 2/3 trials in melanoma and NSCLC initiated.
EIK1003: Dose escalation completed; Phase 2 dose optimization trial first patient dosed; global site selection for Cohort 1D started.
EIK1005 (WRN helicase inhibitor): Phase 1/2 trial began dosing Feb 2026; two abstracts accepted for ASCO.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eikon Therapeutics, Inc. reported first quarter 2026 results: net income $83.0 million.

Period: first quarter 2026
Net income: $83.0 million
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders was $83.0 million for the first quarter of 2026, as compared to $74.5 million for the prior-year period.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Eikon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.